Refine by
Blood Glucose Articles & Analysis: Older
76 news found
These agents work by various means ranging from increasing insulin sensitivity to promoting urine glucose excretion, in order to safely lower blood sugar levels and promote diabetic patients’ outcomes. ...
Creative Enzymes, a leading provider of high-quality enzymes and biochemicals, is proud to announce the addition of Semaglutide to its comprehensive product portfolio. This novel glucagon-like peptide-1 (GLP-1) receptor agonist has generated significant excitement within the pharmaceutical and life sciences industries due to its remarkable efficacy in managing type 2 diabetes. Semaglutide ...
Below are the main microsphere and microneedle solutions provided by CD Formulation: Microsphere and Microneedle Patch Preparation ServicesCD Formulation's research team offers a wide range of microneedle preparations with smooth tip surfaces and clear tip details, for melatonin microneedle patch, parathyroid hormone microneedle patch, exenatide microneedle patch, insulin microneedle patch, and ...
Data from pivotal PHOTON trial demonstrate long term efficacy of aflibercept 8 mg with extended intervals comparable to Eylea (aflibercept 2 mg) at fixed 8-weekly dosing over two years Patients assigned to a 16-week dosing regimen at baseline received a mean of 7.8 injections (6 fewer than Eylea) Safety profile of aflibercept 8 mg in diabetic macular edema (DME) remains comparable to Eylea ...
ByBayer AG
The treatment of T1D consists of insulin treatment to control hyperglycemia. In people with T1D, blood glucose intervention targeting HbA1c levels ≤7% can slow onset and progression of kidney disease. ...
ByBayer AG
New Subgroup and further analyses from PULSAR, PHOTON and CANDELA provide insights into durability results of extended treatment intervals, patient characteristics as well as efficacy and safety of intravitreal aflibercept 8 mg In total, 18 presentations on aflibercept 8 mg and Eylea (aflibercept 2 mg) reinforce Bayer’s commitment to advancing treatment of patients with exudative retinal ...
ByBayer AG
Submission to the Ministry of Health, Labor, and Welfare (MHLW) in Japan for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) is based on positive results of phase III clinical trials, PULSAR and PHOTON In both trials, aflibercept 8 mg demonstrated unprecedented durability results with treatment intervals of up to 16 weeks, with ...
ByBayer AG
The awarded patent, Apparatus for in vivo dielectric spectroscopy (US20200217809A1), focuses on sensor technology that is 100% non-invasive and continuously monitors blood glucose in a way that does not involve blood oxidase, but rather dielectric spectroscopy and radio frequency. ...
ByAlertgy
Alertgy, the biotech startup that’s in the race to be the first company to develop an entirely non-invasive glucose monitoring system is proud to welcome a new hire in the Engineering Department: Benjamin Freer joins Alertgy as Director of Engineering/Principal Sensor Engineer. ...
ByAlertgy
A Flexible Hybrid Electronic Wristband Sensor Platform will be developed to allow for non-invasive blood glucose monitoring, along with other sensing functionality for military personnel,” says Alertgy CEO Marc Rippen. Increased Engineering Capabilities This new location gives Alertgy 2,500 square feet to continue developing ...
ByAlertgy
This will in turn help to increase Alertgy’s ability to accurately monitor blood glucose in real-time during upcoming 3rd party studies and FDA clinical trials. ...
ByAlertgy
Addressing an alternative pathway, Kerendia offers protection as it selectively binds to the MR receptor, blocking harmful effects of MR overactivation. “Even when blood glucose levels and blood pressure are well-controlled, the risk of kidney disease progression and cardiovascular events remains high in patients with chronic kidney ...
ByBayer AG
Filing for aflibercept 8 mg in neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME) is based on positive results of clinical trials, PULSAR and PHOTON In both trials, aflibercept 8 mg demonstrated unprecedented durability results with treatment intervals of up to 16 weeks, with comparable visual acuity as well as rapid and resilient fluid control to the ...
ByBayer AG
As part of our longstanding commitment to supporting numerous relief efforts around the world, LifeScan is working with the non-profit humanitarian organization, Direct Relief, to respond to the urgent need to supply much-needed blood glucose testing supplies to the many Ukrainians now without access to critical health products. ...
ByLifeScan
Diabetes is a chronic disease, that causes blood sugar levels in your body to become too high, either due to your body not being able to respond properly to insulin or due to your body not being unable to produce any at all. ...
” Benefit of Supportive Technology in the Palm of Your Hand Blood glucose meters (BGM) are vital and approximately 95% of people with diabetes who rely on glucose testing use a blood glucose meter. ...
ByLifeScan
Aflibercept 8 mg demonstrated non-inferior vision gains to Eylea® (aflibercept 2 mg) with 83% of patients with neovascular (wet) age-related macular degeneration (nAMD) and 93% of patients with diabetic macular edema (DME) maintaining dosing intervals of 12 weeks or longer through week 48 Superior fluid control in nAMD and robust disease control through to week 48 in nAMD and DME In both ...
ByBayer AG
Demonstrating competence in peptide R&D, production, and sales integration, the US-based chemical supplier Alfa Chemistry recently announced the launch of its peptide product line for researchers across the globe. After this move, a wide range of high-quality extracted peptides, including hydrolyzed protein peptides, fish collagen peptides, marine fish oligopeptides, oyster peptides, sea ...
An article presenting analyses of Continuous Glucose Monitoring (CGM) data from the randomised, placebo-controlled Phase 2b trial DIAGNODE-2 that assessed three intralymphatic injections of the therapeutic diabetes vaccine Diamyd®, has been published in the peer-reviewed scientific journal The Journal of Clinical Endocrinology & Metabolism (JCEM). ...
Roughly 8% of U.S. adults suffer from persistent or chronic back pain. That’s around 65 million people who are prevented from engaging in daily activities. Many are forced to miss days of work due to injury. With rising healthcare costs, many back pain sufferers think that they are left without a real solution, until they try epidural injections. An epidural injection is the infusion of ...